{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06123026",
            "orgStudyIdInfo": {
                "id": "STU00218555"
            },
            "organization": {
                "fullName": "Northwestern University",
                "class": "OTHER"
            },
            "briefTitle": "Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion",
            "officialTitle": "Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion: a Randomized Controlled Trial",
            "therapeuticArea": [
                "Other"
            ],
            "study": "pharmacological-inhibition-of-lactation-after-to-week-abortion"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-18",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-10-28",
            "studyFirstSubmitQcDate": "2023-11-07",
            "studyFirstPostDateStruct": {
                "date": "2023-11-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-28",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Northwestern University",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called \"cabergoline\" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms."
        },
        "conditionsModule": {
            "conditions": [
                "Lactation Suppressed",
                "Second Trimester Abortion"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "whoMasked": [
                        "PARTICIPANT"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 200,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cabergoline",
                    "type": "EXPERIMENTAL",
                    "description": "1mg oral cabergoline administered once after patient's procedure",
                    "interventionNames": [
                        "Drug: Cabergoline"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "1 tablet encapsulated placebo by Investigational Drug Pharmacy administered once after patient's procedure",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Cabergoline",
                    "description": "1mg oral cabergoline given to participants once",
                    "armGroupLabels": [
                        "Cabergoline"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "1 encapsulated placebo tablet given to participants after procedure",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "breast symptoms",
                    "description": "Using the bristol breast inventory to assess breast symptoms (engorgement, lactation, etc).",
                    "timeFrame": "3 days post procedure and two weeks post procedure"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* pregnant individuals seeking termination of pregnancy after 16w0d gestation and up to 19w6d gestation. this includes management of intrauterine demises\n* ages 18 to 50\n* con provide informed consent in English\n\nExclusion Criteria:\n\n* Age under 18 or above 50\n* gestational ages before 16 weeks 0 days or after 20 weeks 0 days\n* unable to provide written consent in English\n* hypertensive disorder\n* uncontrolled hypertension or known hypersensitivity to ergot derivatives\n* History of cardiac valvular disorders\n* history of pulmonary fibrosis\n* documented bipolar schizophrenia\n* documented allergy to medication, including lactose intolerance (placebo pill involves lactose)",
            "healthyVolunteers": true,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "maximumAge": "50 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "locations": [
                {
                    "facility": "Northwestern Medical Center",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Leanne McCloskey",
                            "role": "CONTACT",
                            "phone": "312-926-8678",
                            "email": "erin.fleurant@nm.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077465",
                    "term": "Cabergoline"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000978",
                    "term": "Antiparkinson Agents"
                },
                {
                    "id": "D000018726",
                    "term": "Anti-Dyskinesia Agents"
                },
                {
                    "id": "D000018491",
                    "term": "Dopamine Agonists"
                },
                {
                    "id": "D000015259",
                    "term": "Dopamine Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1806",
                    "name": "Cabergoline",
                    "asFound": "Plerixafor",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4295",
                    "name": "Antiparkinson Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7473",
                    "name": "Dopamine",
                    "relevance": "LOW"
                },
                {
                    "id": "M20595",
                    "name": "Dopamine Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M17962",
                    "name": "Dopamine Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnDyAg",
                    "name": "Anti-Dyskinesia Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "CaAg",
                    "name": "Cardiotonic Agents"
                }
            ]
        }
    },
    "hasResults": false
}